AstraZeneca, Eolas in $145m deal for anti-smoking drug
This article was originally published in Scrip
Carlsbad, California-based private biotechnology firm Eolas Therapeutics could earn up to $145m in upfront, clinical and regulatory milestone fees plus royalties from AstraZeneca under an agreement to develop an orexin-1 receptor antagonist (EORA) for smoking cessation and other indications.
You may also be interested in...
Chief medical officer Samit Hirawat outlines R&D successes – though there have been some setbacks since it bought Celgene for $74bn last year – and the company’s commitment to clinical trial diversity.
Private Company Edition: Also, Medicxi’s new €200m fund will be reinvested in a portfolio of six life science companies and Silverback more than doubled its 2020 money with an $85m series C round.
In last year’s acquisition, Bristol Myers Squibb agreed to pay Celgene investors another $9 per share based on three approvals, including idecabtagene vicleucel (bb2121) by 30 March 2021.